Communiqués de presse Archive - Page 16 of 21 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes

OSE Immunotherapeutics to Present at SITC Annual Meeting And Additional Summits

OSE Immunotherapeutics Provides COVID-19 Vaccine Update on CoVepiT

OSE Immunotherapeutics Presents OSE-230

OSE Immunotherapeutics Announces Publication for Selective Antibody Antagonist BI765063

OSE Immunotherapeutics Receives European Patent Notice of Allowance for FR104

OSE Immunotherapeutics Presents Positive Step-1 Phase 3 Results for Tedopi® in NSCLC

OSE Immunotherapeutics Reports First Half 2020 Results

OSE Immunotherapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

OSE Immunotherapeutics Publishes Positive Preclinical COVID-19 Vaccine Results

OSE Immunotherapeutics To Present Step-1 Results of Phase 3 Clinical Trial of Tedopi® ‘Atalante 1’

Précédent
1
…
13
14
15
16
17
18
19
…
21
Suivant